跳至主要内容
临床试验/CTRI/2017/06/008817
CTRI/2017/06/008817尚未招募未知

Effect of Concurrent Administration of Intravenous Naloxone on Opioid Agonist Effects of Intravenous Buprenorphine: A Double-blind, Within-subject, Randomized, Cross-over Study among Opioid Dependent Subjects

ational Drug Dependence Treatment Centre AIIMS0 个研究点目标入组 12 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Diagnosed patients of opioid dependence (as per ICD 10 criteria)
  • 2. History of injecting drug use ever in life
  • 3. Should be on sublingual buprenorphine or buprenorphine-naloxone combination tablets from NDDTC for at least 3 months
  • 4. Maintained on sublingual buprenorphine or buprenorphine-naloxone combination dose of 8 to 18 mg per day
  • 5. Received sublingual buprenorphine or buprenorphine-naloxone combination tablets on at least 75% of the scheduled occasions in previous three months.
  • 6. Willing to provide informed consent
  • 7. Able to read and write

排除标准

  • 1. Current dependence on substances other than opioids (except nicotine)
  • 2. Use of any other psychoactive substance (except nicotine and prescribed psychotropic medications) within the last 72 hours
  • 3. Any current general medical illnesses or neurological disorder, psychiatric illnesses or disability hampering communication / informed consent process.

研究者

发起方
ational Drug Dependence Treatment Centre AIIMS

相似试验